Mustang Bio to Present at the CAR-TCR Summit 2017
September 05 2017 - 7:30AM
Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech
(NASDAQ:FBIO) Company focused on the development of novel
immunotherapies based on proprietary chimeric antigen receptor
engineered T cell (CAR T) technology, today announced that the
Company will present and also participate in a panel session at the
CAR-TCR Summit 2017, to be held September 5-8 at the Seaport Hotel
& World Trade Center in Boston.
Details on the oral presentation are as follows:
Title: CAR T Cell Therapy for Brain
Tumors: Logistical Challenges and Opportunities
Presenter: Sadik Kassim, Ph.D., Vice
President, Process and Analytical Development, Mustang Bio, Inc.
Track: CAR-TCR Commercialization Stream
Date and Time: Wednesday, September 6, 2017,
11:50 a.m. – 12:20 p.m. EDTLocation: Waterfront
2/3 Room
Details on the panel session are as follows:
Title: What are the next generation
innovations to improve solid tumor efficacy?
Panelist: Sadik Kassim, Ph.D., Vice
President, Process and Analytical Development, Mustang Bio, Inc.
Track: CAR-TCR Discovery Stream Date
and Time: Wednesday, September 6, 2017, 5:50 p.m. –
6:50 p.m. EDTLocation: Cityview Room
For additional information on the CAR-TCR Summit 2017, please
visit: http://car-tcr-summit.com/.
About Mustang BioMustang Bio, Inc., a
subsidiary of Fortress Biotech, Inc., is a clinical‐stage
biopharmaceutical company focused on the development and
commercialization of novel cancer immunotherapy products designed
to leverage the patient’s own immune system to eliminate cancer
cells. Mustang aims to acquire rights to these technologies by
licensing or otherwise acquiring an ownership interest, funding
research and development, and outlicensing or bringing the
technologies to market. Mustang is currently developing proprietary
chimeric antigen receptor (CAR) engineered T cell (CAR T)
technology, which was licensed from Drs. Stephen Forman and
Christine Brown’s laboratory at the City of Hope National Medical
Center (“COH”). Mustang and COH have established a research
agreement to develop CARs across multiple cancers. Mustang’s lead
programs are in Phase 1 trials at COH: MB-101 for the treatment of
brain cancer, and MB-102 as a therapeutic agent in acute myeloid
leukemia. Mustang is registered under the Securities Exchange Act
of 1934, as amended, and files periodic reports with the U.S.
Securities and Exchange Commission. For more information, visit
www.mustangbio.com.
About Fortress BiotechFortress
Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated
to acquiring, developing and commercializing novel pharmaceutical
and biotechnology products. Fortress develops and commercializes
products both within Fortress and through certain of its subsidiary
companies, also known as Fortress Companies. In addition to its
internal development programs, Fortress leverages its
biopharmaceutical business expertise and drug development
capabilities and provides funding and management services to help
the Fortress Companies achieve their goals. Fortress and the
Fortress Companies may seek licensings, acquisitions, partnerships,
joint ventures and/or public and private financings to accelerate
and provide additional funding to support their research and
development programs. For more information, visit
www.fortressbiotech.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
growth strategy and product development programs, and any other
statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: the risk that Mustang will not be
able to advance its research programs; risks related to the timing
of starting and completing of clinical trials; risks inherent in
research and development activities; risks related to its growth
strategy; its ability to obtain, perform under and maintain
financing and strategic agreements and relationships; uncertainties
relating to preclinical and clinical testing; its dependence on
third-party suppliers; its ability to attract, integrate, and
retain key personnel; the early stage of products under
development; its need for substantial additional funds; government
regulation; patent and intellectual property matters; competition;
as well as other risks described in Mustang’s public filings and
reports. Mustang expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
Contacts:
Jaclyn Jaffe
Mustang Bio, Inc.
(781) 652‐4500
ir@mustangbio.com
Fortress Biotech Media Relations
Laura Bagby
6 Degrees
(312) 448-8098
lbagby@6degreespr.com
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024